- 565studies in the library match, of 29,380
- 223name it in the title
- 2020–2026years published
- 499peer-reviewed articles
The query: title or abstract mentions "p-tau217", "ptau217" or "phosphorylated tau 217", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 29,380 study records, as of 2026-11-08. Every count on this page comes from that match. The matched list as JSON.
Tau phosphorylated at position 217 rises in blood early in Alzheimer's disease and tracks amyloid plaque build-up more closely than most other blood markers. Several laboratory assays measure it, and they are not interchangeable: each has its own cut-off and its own accuracy figures.
Papers report accuracy against an amyloid PET scan or a spinal fluid test, usually as an area under the curve (AUC) together with sensitivity and specificity at a chosen cut-off.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person: a doctor who knows the person's history is the only one who can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 565 matched records are quoted; each links to its study page and from there to the paper.
“Plasma p-tau217-eligible participants were enrolled (N = 2196), with Clinical Dementia Rating (CDR) scale-Global score (CDR-GS) of 0 (n = 1202) and 0.5 (n = 664).”
“Mean percentage change in plasma p-tau217 in the SAMe group was an increase of 53.22 (standard deviation [SD] 159.19) compared to 25.34 (SD 94.83) in the placebo group (standardized mean difference 37.58, 95% confidence interval -32.61, 107.76; p = 0.288).”
“Conclusions and relevance This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts.”
“Notably, the p-tau217/Aβ 42 ratio on automated platforms provided a significant incremental AUC gain of 0.025 (95% CI: 0.005 to 0.045; I2 = 0%) compared to single-analyte assays, effectively bridging the performance gap with MS.”
“Changes in plasma pTau217 and glial fibrillary acidic protein were significantly correlated with the Centiloid percent change in amyloid (Spearman rank correlation coefficient [R] = 0.484 [95% CI, 0.359-0.592]; P < .001 and R = 0.453 [95% CI, 0.306-0.579]; P < .001, respectively) following treatment.”
“HIGHLIGHTS: p-tau217 and p-tau231 correlate with Aβ-PET and respond to Aβ-plaque lowering therapies.”
“In summary, both mass spectrometry- and immunoassay-based p-tau217 tests generally perform well in identifying Aβ-PET, tau-PET and cognitive abnormalities, but %p-tau217WashU performed significantly better than all the examined immunoassays.”
“Sequential selection using plasma phosphorylated tau at threonine 217 (p-tau217) and then tau-PET reduced the number of participants required for a clinical trial by 94%, compared to a 76% reduction when using plasma p-tau217 alone.”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 16 |
| Other clinical trial | 12 |
| Cohort or longitudinal study | 123 |
| Case-control study | 2 |
| Cross-sectional study | 66 |
| Other recorded design | 6 |
| No design recorded | 340 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 193 | |
| 2025 | 217 | |
| 2024 | 71 | |
| 2023 | 38 | |
| 2022 | 24 | |
| 2021 | 18 | |
| 2020 | 4 | |
| 2019 | 0 | |
| 2018 | 0 | |
| 2017 | 0 |
Other counts within the matched set
| Peer-reviewed articles | 499 |
| Marked open access in the record | 277 |
| Rated "high" evidence strength in alzhub's summary | 42 |
| Rated "moderate" evidence strength in alzhub's summary | 247 |
| Rated "low" evidence strength in alzhub's summary | 271 |
| No evidence-strength rating | 5 |
| Records stating a participant count | 373 |
| Median participants (those records) | 348 |
| Largest participant count | 63,124 |
Within the 565 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that report an AUC | 148 | the abstract also contains "AUC" or "area under" |
| …that compare more than one assay | 70 | the abstract also contains "assays" or "head-to-head" |
| …that mention kidney function | 29 | the abstract also contains "kidney", "renal", "eGFR" or "chronic kidney" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
- Diagnostic performance of plasma p-Tau217, p-Tau181, and p-Tau231 across the Alzheimer's disease continuum: a network meta-analysis
- A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
- Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
- Prognostic value of plasma %p-tau217 in cognitively unimpaired older adults
- Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta-analysis
- A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
- Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
- Cross-cohort validation and cutpoint estimation of the Janssen plasma p-tau217+ assay in predominantly cognitively normal community studies
- Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
Systematic reviews and meta-analyses in the set
16 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Association between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: a systematic review
- Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis
- Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
- Plasma Phosphorylated Tau 217 and Amyloid Burden in Older Adults Without Cognitive Impairment: A Meta-Analysis
- Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Newest matched studies
- Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease
- Blood-based biomarkers across the Alzheimer's disease continuum in older Korean population
- Cognition in healthy aging, ages 36 to 108: Associations with dementia risk factors and neurodegenerative disease biomarkers
- Detection of tau spatial extent using MK6240 and flortaucipir PET
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Alzheimer's & dementia : the journal of the Alzheimer's Association | 106 |
| medRxiv | 31 |
| Alzheimer's research & therapy | 28 |
| Alzheimer s & Dementia | 27 |
| Neurology | 19 |
Questions
- What is p-tau217?
- A form of the tau protein with a phosphate attached at position 217. Its level in blood rises as amyloid plaques accumulate, which is why it is used as a blood marker of Alzheimer's pathology.
- How many studies on p-tau217 does alzhub hold?
- 565 of the 29,380 study records in alzhub's library match the query "title or abstract mentions "p-tau217", "ptau217" or "phosphorylated tau 217""; 223 of them name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 16 systematic review or meta-analysis, 12 other clinical trials, 123 cohort or longitudinal studys, 2 case-control studys, 66 cross-sectional studys; 340 record no design.
- What is the most recent study in the set?
- "Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study" (Research Square, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Alzheimer's & dementia : the journal of the Alzheimer's Association (106); medRxiv (31); Alzheimer's research & therapy (28), counted across the matched records.
Read on
- Blood tests for Alzheimer'salzhub's sourced evidence page on the tests.
- Blood tests for Alzheimer's: the studiesAll blood markers together.